% % 0期刊文章%艾米Quek)一个安德鲁·麦肯%万带兰列侬% Jayawant Mandrekar %一个焦Yujuan拉斐尔人工% %一个奇亚拉Costanzi %一个院长Wingerchuk布莱恩Weinshenker % %克劳迪娅Lucchinetti % Sean Pittock伊丽莎白•舒斯特% % T年龄和性别对Aquaporin-4自身免疫的影响(S60.002) % D J神经病学2012% % P S60.002-S60.002 % V 78% N 1补充% X目的:确定性别和年龄分布Aquaporin-4 (AQP4)自身免疫使用数据来源于临床服务56464患者样本的实验室检测。首页女性比男性更容易受背景neuromyelitis视(动),但女:男(F: M)研究之间的性别比例相差很大。AQP4-specific自体抗体(AQP4 / NMO-IgG)是一种临床验证血清生物标志物,区分动及其部分形式(NMO-spectrum障碍)多发性硬化症。设计/方法:2005年10月至2011年1月,56464个标本检测AQP4-IgG通过免疫荧光测定基质组成正常成年小鼠的大脑,肾脏和肠道组织。AQP4-IgG中检测出2960个病人(5.2%)。信息可用性2771例和2743例年龄。结果:血清反应阳性的患者比血清反应阴性的患者(平均年龄46 (SD 16)和42 (SD 15)年;p < 0.001)。女性比男性多了(n = 37662年和16810年分别;p < 0.001)。2743血清反应阳性的患者中,146(5.3%)儿科(≤18年)和333年(12.1%)老年人(> 65岁)。 The sex distribution of 2771 AQP4-IgG seropositive patients was: 2465 women; 306 men (absolute F:M ratio = 8.1:1, p<0.001). After adjusting for the number of women tested, an excess of women persisted (adjusted F:M 3.6:1). Female predominance for AQP4-IgG was more striking in adults (absolute F:M, 8.4:1; adjusted, 3.5:1) than in pediatric patients (absolute F:M, 4.3:1; adjusted, 2.9:1; p<0.001). These findings were concordant in a subgroup of Mayo Clinic AQP4-seropositive patients whose diagnoses were known. The proportion of AQP4 seropositive individuals (detection rate), defined by decade of age, increased exponentially in women after age 50 (p<0.001).Conclusions: AQP4-seropositivity occurs predominantly in women, particularly in individuals >18 years of age. One in six seropositive patients are in the extremes of age. In women, but not men, AQP4-IgG seropositivity increases exponentially beyond age 50.Supported by: Guthy-Jackson Charitable Foundation and NIH (NS065829).Disclosure: Dr. Quek has nothing to disclose. Dr. McKeon has nothing to disclose. Dr. Lennon has nothing to disclose. Dr. Mandrekar has nothing to disclose. Dr. Iorio has nothing to disclose. Dr. Jiao has nothing to disclose. Dr. Costanzi has nothing to disclose. Dr. Weinshenker has received personal compensation for activities with Novartis and Biogen Idec as a participant on a monitoring board. Dr. Weinshenker has received (royalty or license fee or contractual rights) payments from Mayo Medical Ventures. Dr. Weinshenker has received research support from Guthy Jackson Charitable Foundation. Dr. Wingerchuk has received research support from Genentech, Inc,, Genzyme Corporation, Alexion and the Guthy-Jackson Charitable Foundation. Dr. Lucchinetti has nothing to disclose. Dr. Shuster has nothing to disclose. Dr. Pittock has received research support from Alexion Pharmaceuticals, Inc.Thursday, April 26 2012, 15:00 pm-16:30 pm %U